Sinclair Pharma Share Discussion Threads

[steeplejack] 13/2/2015 09:17

Tosca have done this before.Built an interest close to the 29.9% trigger and then effectively put the company into play.The driver is that the company is undervalued.

[dealit] 12/2/2015 21:15

I have never understood why Tosca built their holding to 29%+, they could have bid for SPH with 30% of the shares and most probable bought for 34p. I would feel that Tosca built up their stock knowing a buyer is in the wings, Tosca cannot loose, IMHO.

[eggbaconandbubble] 12/2/2015 19:43

No, that's correct. They sold 2.18 million shares in QUINDELL not Sinclair! Which is about £1.5m. May not be significant or could be a start to building up a war chest!

[eggbaconandbubble] 12/2/2015 19:33

In the Daily Mail today. I might have figure wrong or more likely the Mail has! I'll check.

[dealit] 12/2/2015 17:47

"egg" how do you know this? Tosca have 146,709,360 shares if they have sold 1.5m not a big loss.

[steeplejack] 12/2/2015 14:50

Thought you meant Sinclair at a glance.

[eggbaconandbubble] 12/2/2015 13:08

Tosca fund has just sold 1.5 million quids worth of its shares in Quindell........!

[eggbaconandbubble] 11/2/2015 17:12

Thompson's Irish Breakfast, one sugar (demerara) and Carnation milk....lovely jubbly!
Kettle on!

[ifthecapfits] 11/2/2015 16:08

a cup of tea to go with eggs and bacon.

[eggbaconandbubble] 11/2/2015 15:43

mmmmh....something brewing????

[soundbuy] 11/2/2015 09:53

Large buys this am. ...........

[steeplejack] 09/2/2015 17:41

Yes,there's the statement and if the company hadn't said that it was potentially looking to sell the whole company,we wouldn't be having to weary ourselves with all these Rule 8 Takeover Code disclosures!!I think we can take it as read (especially given Martin Hughes past behaviour when he's built up such a substantial stake in a company )that if a satisfactory offer comes along for the whole outfit,he'll take it. Game ,set and match.

[gobbie100] 09/2/2015 17:11

From the original statement. A full sale is one of the potential options. I suspect the two bits generating interest would be the aesthetics and also flammacerium now that it has orphan status in the US.

'Accordingly, the Board has decided to appoint Rothschild to assist it in evaluating the optimum way to realise the considerable value in the Company which may, or may not, include the sale of all or part of the Company. The Board believes that Sinclair has a secure future as an independent business and will only engage with those willing to recognise and support the Company's significant growth potential'.

[eggbaconandbubble] 09/2/2015 15:37

I don't think at any point did the company say it was putting itself up for sale. It was apparently some journalistic poetic licence when the Dail Mail stated they had had ten or more approaches from various companies. My hunch is that they are intending to sell parts of the company, possibly holding onto the aesthetics bit which include Silhouette.
I could be very wrong.
As the tipsters say. HOLD!

[katie1234] 09/2/2015 14:40

Thanks Red Ninja and Steeplejack for your responses. Hopefully when we do hear something the price will be a good one for all private shareholders. I've not had much success with my AIM shares so far, hopefully I may get something back with this one!

[steeplejack] 09/2/2015 13:57

Katie,

When Sinclair announced that it was putting itself up for sale it triggered Rule 8 disclosure rules relating to takeovers.Hence we now have a plethora of small,pretty unimportant RNSs relating to dealing.Rule 8.5 is explained below and applies to brokers who act for clients but can also trade their own proprietary book.

"Form 8.5 (EPT/RI) Public Dealing Disclosure by an exempt principal trader with recognised intermediary status dealing in a client-serving capacity Rule 8.5(c)(ii)"

There are other Rule 8 sub clauses pertaining to all and sundry to cover other parties

How long will it take to see a buyer emerge?Well,how long is a piece of string! I would have guessed that due diligence by interested parties could take 6 months,so I wouldn't expect to hear anything until late April perhaps from interested parties.It's all very sensitive nowadays,so all they can really say is that talks are ongoing.

[red ninja] 09/2/2015 12:38

Hi Katie,

Peel Hunt is a trader ie they buy and sell SPH shares to make a profit
(hopefully for them). The profit may be small and we don't know what the profit is
because min and max figures are not given and not all shares may have been traded at the max or min price.

[katie1234] 09/2/2015 11:01

Hi I am new to this board, but have been with SPH for a while. Please can someone explain to me what all the 'Form 8.5 (EPT/RI) - Sincliar IS Pharma PLC's mean? I can't understand when it shows buys and sells in the same document, when all the deals are made at similar prices, i.e. there isn't much difference between the buy and sell price. Also, has anyone got any idea how long it takes to sell a company, bearing in mind there were supposedly a few companies ready to make bids? Thanks

[meijiman] 27/1/2015 08:45

Maybe flush out a bidder. Looks like a win-win here.

[ifthecapfits] 27/1/2015 07:45

Hope the share price responds accordingly todat. As you say - reads well, with good growth.

[soundbuy] 27/1/2015 07:34

Reads well............

[dafad] 27/1/2015 07:16

RNS Number : 1839D

Sinclair IS Pharma PLC

27 January 2015

Trading Update

London, 27 January 2015 Sinclair IS Pharma plc (AIM:SPH.L) ("Sinclair" or the "Group"), the international specialty pharma company, announces a trading update for the six months ended 31 December 2014 ahead of the publication of interim results on 17 February 2015.

The Group continues to perform well and in line with the Board's expectations. Revenues for the six months ended 31 December 2014 were GBP32.0 million, compared to GBP24.5 million for the same period last year representing reported growth of 31% and 37% on a constant currency basis. Revenues from the Group's aesthetic portfolio grew strongly to GBP13.6 million (43% of total revenues) with the recently acquired brands Silhouette, Perfectha and Ellansé all contributing significantly as detailed below.

Silhouette(R) sales reached GBP2.7 million in the first half, representing growth of 52% (at constant currency) over the same period in 2013 (pre-acquisition). The Group has successfully repatriated direct rights for Silhouette(R) in the UK and France during H1 and in Germany from January 2015, and expects to conclude negotiations in Spain this month.

Perfectha(R) delivered revenues of GBP3.7 million in the first half, with a strong performance in Europe where the Group has launched Perfectha(R) through all Sinclair's direct operations. Revenue in these territories grew to GBP0.8 million from GBP0.2 million in the same period in 2013 (pre-acquisition). Ellansé(TM) contributed revenues of GBP1.8 million in the first half, slightly below Board expectations but affected by distributor stocking patterns particularly in Korea and Russia. Sculptra revenues at GBP2.3 million were ahead of management expectations.

Q2 trends in the Aesthetics franchise as a whole were particularly encouraging. The growth rate of the Aesthetics franchise has accelerated through the first half following an initial focus on revamping training, education and PR programmes. After a very successful Worldwide Experts Meeting held in Barcelona in October which was attended by almost 1,300 physicians, sales of Silhouette(R) have accelerated growing by 156% (at constant currency) in the final three months of 2014 over the previous quarter and Silhouette(R) training courses are currently oversubscribed. In Western Europe, the number of active Perfectha(R) users has increased by over 120% from around 450 users in June 2014 to over 1,000 by December 2014 and the number of active Ellansé(TM) users also doubled to 400 over the same period.

During the first half, the 510(k) application for Silhouette(R) Instalift was filed in the US. The file is being reviewed by the FDA and management expect approval in 2015. Approval had been envisaged for Russia during H1 FY15 but due to political factors this is now viewed as unlikely in the near term.

Country operations performed strongly in H1 reaching revenues of GBP17.8 million (H1 FY14 GBP16.7 million). Importantly aesthetic sales contributed revenues of GBP6.0 million with all brands performing well. The launch of Ellansé(TM) by Sinclair in France and Spain has been very well received with Ellansé(TM) sales in Sinclair direct territories increasing to GBP0.5m from GBP0.2m in the same period in 2013 (pre-acquisition).

International operations revenues reached GBP14.2 million (H1 FY14 GBP7.8 million) with the addition of revenues from the acquired aesthetic brands as well as from continuing growth of Atopiclair(R), Papulex(R) and Kelostretch(R) in Asia. Partner stocking patterns and visibility on international orders provides confidence of continuing strong growth for the full year in the International business.

EBITDA for the period is expected to be in line with the Board's expectations. Historical seasonality in both Sinclair's sales and marketing spend produces higher sales in the second half. The Board expects this trend to continue, noting the industry tendency for stronger Aesthetics sales in late spring and the Company's improving Aesthetics growth trends. However, continued weakness of the Euro is providing ongoing headwinds.

In line with Board expectations, net debt increased to GBP44.2 million at 31 December 2014, from GBP40.2 million at 30 June 2014. Net debt at 31 December 2014 was made up of cash of GBP13.4 million and borrowings of GBP57.6 million.

The strategic review announced on 25 November 2014 is ongoing and there is no further update at this stage.

Chris Spooner, CEO, commented "Sinclair has made a rapid entry into Aesthetics based on a highly differentiated portfolio and 'facial rejuvenation' approach. The Company has multiple avenues for continued high growth across several products and territories, while prospects for the US provide an opportunity to take the company to a new level.

[eggbaconandbubble] 26/1/2015 19:05

Plastic surgery on the decline.



Interesting to note that face lifts are one area that showed some increase in turnover.

[ifthecapfits] 26/1/2015 08:31

Where's this supposed bid then?

[soundbuy] 22/1/2015 16:43

Somebody keen today..............